Skip to main content

Advertisement

SpringerLink
Log in

High Expression of Interleukin-22 and Its Receptor Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The cytokine interleukin-22 (IL-22) and its receptor are present in the tumor microenvironment. Their function in pancreatic ductal adenocarcinoma (PDAC) remains largely unknown. The goal of the present study was to measure the expression of IL-22 and IL-22R in PDAC and assess their relationship with clinicopathological features and prognosis.

Methods

The expression of IL-22 and IL-22R was evaluated by immunohistochemistry in PDAC tissues from 57 patients and by Western blotting in six tumors and adjacent nontumor tissues. A statistical analysis was conducted to assess the relationship between levels of expression, clinicopathological factors, and overall survival. In addition, the relationship between the expression of IL-22 and IL-22R and invasion was assessed by Western blotting and transwell assay with the PDAC cell lines PANC1 and BxPC3.

Results

Positive IL-22 staining was detected in PDAC tissues and adjacent nontumor tissues. Positive IL-22R staining was detected in PDAC cells. High expression of IL-22 and IL-22R correlated significantly with lymph node involvement. IL-22 increased the phosphorylation of signal transducer and activator of transcription3, the expression of matrix metalloproteinase 9, and the invasion in PANC1 and BxPC3 cells in vitro while silencing of IL-22R RNA caused opposite effects. Most importantly, overall survival was significantly poorer in patients with high expression of IL-22 and IL-22R than in those with low expression.

Conclusions

These findings reveal the positive role of IL-22 and IL-22R in invasion and metastasis in human PDAC. IL-22 and IL-22R may be suitable independent prognostic markers in PDAC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yeo TP, Lowenfels AB. Demographics and epidemiology of pancreatic cancer. Cancer J. 2012;18:477–84.

    Article  PubMed  Google Scholar 

  2. Kadaba R, Birke H, Wang J, et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol. 2013;230:107–17.

    Article  CAS  PubMed  Google Scholar 

  3. Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266–76.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000;164:1814–9.

    CAS  PubMed  Google Scholar 

  5. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity. 2004;21:241–254.

    Article  CAS  PubMed  Google Scholar 

  6. Gelebart P, Zak Z, Dien-Bard J, et al. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol. 2011;4:9–19.

    PubMed Central  PubMed  Google Scholar 

  7. Zhang W, Chen Y, Wei H, et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res. 2008;14:6432–9.

    Article  CAS  PubMed  Google Scholar 

  8. Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 2012;491:259–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Zhuang Y, Peng LS, Zhao YL, et al. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother. 2012;61:1965–75.

    Article  CAS  PubMed  Google Scholar 

  10. Jiang R, Tan Z, Deng L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011;54:900–9.

    Article  CAS  PubMed  Google Scholar 

  11. Zhu W, Cai MY, Tong ZT, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial–mesenchymal transition. Gut. 2012;61:562–75.

    Article  CAS  PubMed  Google Scholar 

  12. Curd LM, Favors SE, Gregg RK. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol. 2012;168:192–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Jiang R, Wang H, Deng L, et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer. 2013;13:59.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Xu W, Chen GS, Shao Y, et al. Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells. Cancer Lett. 2013;332:11–8.

    Article  CAS  PubMed  Google Scholar 

  15. Tkach M, Rosemblit C, Rivas MA, et al. p42/p44 MAPK-mediated Stat3 Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer. 2013;20:197–212.

    Article  CAS  PubMed  Google Scholar 

  16. Chen Y, Wang J, Wang X, et al. STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J Breast Cancer. 2013;16:40–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Guo K, Ma Q, Li J, et al. Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol Cancer Ther. 2013;12:264–73.

    Article  CAS  PubMed  Google Scholar 

  18. Li H, Huang C, Huang K, et al. STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS One. 2011;6:e25941.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009;1171:59–76.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Xie TX, Huang FJ, Aldape KD, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006;66:3188–96.

    Article  CAS  PubMed  Google Scholar 

  21. Debidda M, Wang L, Zang H, et al. A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J Biol Chem. 2005;280:17275–85.

    Article  CAS  PubMed  Google Scholar 

  22. Pelletier S, Duhamel F, Coulombe P, et al. Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors. Mol Cell Biol. 2003;23:1316–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Gaemers IC, Vos HL, Volders HH, et al. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem. 2001;276:6191–9.

    Article  CAS  PubMed  Google Scholar 

  24. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Wang X, Lee SO, Xia S, et al. Endothelial cells enhance prostate cancer metastasis via IL6 → androgen receptor → TGFbeta → MMP9 signals. Mol Cancer Ther. 2013;12:1026–37.

    Article  CAS  PubMed  Google Scholar 

  26. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000;17:673–81.

    CAS  PubMed  Google Scholar 

  27. Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122:2050–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The study was supported by the special professor funding of Peking Union Medical College, the Chinese Health Industry Research and Special Fund (No. 201202007), and the National High Tech Research and Development Program of China (863 plan) (No. 2012AA02A212).

Disclosure

There are no financial disclosures from any author.

Author information

Authors and Affiliations

  1. Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tsinghua University, Beijing, China

    Zhang Wen MD, Quan Liao MD, Jianguo Zhao MD, Ya Hu MD, Lei You PhD, Yingxin Wei MD & Yupei Zhao MD, FACS, FRCS

  2. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tsinghua University, Beijing, China

    Zhaohui Lu MD & Congwei Jia MD

Authors
  1. Zhang Wen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Quan Liao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianguo Zhao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ya Hu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lei You PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhaohui Lu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Congwei Jia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yingxin Wei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yupei Zhao MD, FACS, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yupei Zhao MD, FACS, FRCS.

Additional information

Zhang Wen and Quan Liao contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wen, Z., Liao, Q., Zhao, J. et al. High Expression of Interleukin-22 and Its Receptor Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 21, 125–132 (2014). https://doi.org/10.1245/s10434-013-3322-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3322-x

Keywords

Search

Navigation